Table 2.
Comparison between the methods of preparation
| THW only (n = 35) | rhTSH only (n = 58) | Initial THW, followed by rhTSH (n = 82) | |
|---|---|---|---|
| Age (yr) | |||
| Median | 56 | 60 | 55 |
| Range | 24–80 | 20–89 | 20–79 |
| Gender [n (%)] | |||
| Males | 15 (43%) | 28 (48%) | 39 (48%) |
| Females | 20 (57%) | 30 (52%) | 43 (52%) |
| TNM [n (%)] | |||
| M0/Mx | 14 (40%) | 26 (45%) | 30 (37%) |
| M1 | 21 (60%) | 32 (55%) | 52 (63%) |
| AJCC Stage [n (%)] | |||
| I | 6 (17%) | 6 (10%) | 10 (12%) |
| II | 7 (20%) | 19 (33%) | 16 (20%) |
| III | 0 | 1 (2%) | 1 (1%) |
| IV | 17 (49%) | 24 (41%) | 44 (54%) |
| Unknown | 5 (14%) | 8 (14%) | 11 (13%) |
| Distribution of DM [n (%)] | |||
| Lung only | 20 (57%) | 30 (52%) | 42 (51%) |
| Bone only | 9 (26%) | 13 (22%) | 27 (33%) |
| Lung and bone | 6 (17%) | 15 (26%) | 13 (16%) |
| Lung Mets size [n (%)] | |||
| Micro | 18 (75%) | 36 (80%) | 43 (80%) |
| Bone Mets [n (%)] | |||
| Single | 6 (40%) | 9 (32%) | 9 (23%) |
| RAI avid without radiological correlate [n (%)] | 4 (12%) | 16 (28%) | 6 (8%) |
| RAI cumulative administered activity [mCi] | |||
| Median | 522 | 408 | 967a |
| Range | 73–2024 | 75–1167 | 274–3027 |
| Number of RAI treatments (including ablation) | |||
| Median | 2 | 2 | 4a |
| Range | 1–8 | 1–5 | 2–10 |
| Follow-up (median) | 6.9 | 3.4a | 6.9 |
| Range | 1.4–17.1 | 1.3–10.3 | 0.8–20.9 |
| Year of diagnosis of DM [n (%)] | |||
| 1983–1999 | 22 (63%) | 6 (10%)a | 49 (60%) |
| 2000–2010 | 13 (27%) | 52 (90%)a | 33 (40%) |
| Histotype [n (%)] | |||
| PTC | 12 (34%) | 9 (15%) | 19 (23%) |
| Follicular variant PTC | 6 (17%) | 12 (21%) | 14 (17%) |
| Tall cell variant PTC | 2 (6%) | 8 (14%) | 2 (2.5%) |
| Follicular thyroid carcinoma | 6 (17%) | 5 (8%) | 9 (11%) |
| Hürthle cell carcinoma | 0 | 4 (7%) | 2 (2.5%) |
| Poorly differentiated thyroid carcinoma | 8 (23%) | 16 (28%) | 30 (37%) |
| Others | 1 (3%) | 4 (7%) | 6 (7%) |
Mets, Metastases; PTC, papillary thyroid carcinoma.
a
P < 0.05 compared with the other two groups.